Remission in Global Airway Diseases: <scp>EUFOREA</scp> Consensus Paper

The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease-modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR). This EUFOREA consensus aims to establish practical guidance for inducing and maintaining remission in global airway diseases. An international panel of experts in pneumology, rhinology, and allergology convened in Rome (October 2025) to review current evidence and develop consensus statements. The panel achieved consensus on key principles: (i) remission is a therapeutic target independent of disease severity prior to treatment initiation and should not be reserved for severe cases; (ii) CRSwNP with nonallergic eosinophilic asthma, and AR with allergic asthma should be considered features of a single disease rather than comorbidities; (iii) remission should be assessed by each subspecialty separately while warranting combined approaches; (iv) pragmatic definitions prioritizing achievability and clinical utility are recommended; and (v) a 4-week recall window is preferred to assess symptom control within the evaluation of remission and a 12-month period is suggested as the minimal period to define remission. Remission represents an ambitious yet achievable goal, with practical guidance for optimizing patient outcomes.

Authors

Institutions

Publication Details

Journal
Allergy
Published
2026-06-16
DOI
https://doi.org/10.1111/all.70415
Primary Topic
Sinusitis and nasal conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Remission in Global Airway Diseases: EUFOREA Consensus Paper

Guy Brusselle, Riyad Al‐Lehebi, Liam Gabriel Heaney, Benjamin S. Bleier et al.
Allergy
Sinusitis and nasal conditions
article

Remission in Global Airway Diseases: EUFOREA Consensus Paper

Guy Brusselle, Riyad Al‐Lehebi, Liam Gabriel Heaney, Benjamin S. Bleier, J. Christian Virchow, Florence Schleich, Wytske J. Fokkens, Xander Bertels, Frederik Trinkmann, Peter W. Hellings, Corrado Pelaia, Marco Caminati, Valerie J. Lund, Mina Gaga, Martin Wagenmann, Eugenio De Corso, Anju T. Peters, Paola Rogliani, Diego M. Conti, Stella E. Lee, Glenis Scadding, Philippe Gevaert, Vibeke Backer
article en

Abstract

The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease-modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR). This EUFOREA consensus aims to establish practical guidance for inducing and maintaining remission in global airway diseases. An international panel of experts in pneumology, rhinology, and allergology convened in Rome (October 2025) to review current evidence and develop consensus statements. The panel achieved consensus on key principles: (i) remission is a therapeutic target independent of disease severity prior to treatment initiation and should not be reserved for severe cases; (ii) CRSwNP with nonallergic eosinophilic asthma, and AR with allergic asthma should be considered features of a single disease rather than comorbidities; (iii) remission should be assessed by each subspecialty separately while warranting combined approaches; (iv) pragmatic definitions prioritizing achievability and clinical utility are recommended; and (v) a 4-week recall window is preferred to assess symptom control within the evaluation of remission and a 12-month period is suggested as the minimal period to define remission. Remission represents an ambitious yet achievable goal, with practical guidance for optimizing patient outcomes.

Allergy
Northwestern University (US), University of Rome Tor Vergata (IT), University of Verona (IT), Queen's University Belfast (GB), Massachusetts Eye and Ear Infirmary (US), Alfaisal University (SA), University of Liège (BE), University of Mannheim (DE), Heidelberg University (DE), Ghent University Hospital (BE), King Fahd Medical City (SA), Erasmus MC (NL), University Hospital Heidelberg (DE), Agostino Gemelli University Polyclinic (IT), Rigshospitalet (DK), Royal National Orthopaedic Hospital (GB), Ghent University (BE), Magna Graecia University (IT), Massachusetts General Hospital (US), Düsseldorf University Hospital (DE), Queens University (BD), Hygeia Hospital (GR), Centre for Immunity, Infection and Evolution (GB), German Center for Lung Research (DE), European Federation of Allergy and Airways Diseases Patients Associations (BE), Universitätsmedizin Rostock (DE), University Medical Centre Mannheim (DE), Eastman Dental Hospital (GB), Heinrich Heine University Düsseldorf (DE), University College London (GB), Amsterdam University of Applied Sciences (NL), Universidad Autónoma de Madrid (ES), University of Amsterdam (NL), Erasmus University Rotterdam (NL), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 5%
Sinusitis and nasal conditions
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.